New therapeutic indications for botulinum toxins
Identifieur interne : 001E94 ( Istex/Curation ); précédent : 001E93; suivant : 001E95New therapeutic indications for botulinum toxins
Auteurs : Carla Cordivari [Royaume-Uni] ; V. Peter Misra [Royaume-Uni] ; Santiago Catania [Royaume-Uni] ; Andrew J. Lees [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-03.
English descriptors
- KwdEn :
Abstract
The efficacy of botulinum toxin (BTX) without systemic effects has led to the rapid development of applications in neuromuscular disorders, hyperactivity of sudomotor cholinergic‐mediated glandular function, and pain syndromes. The successful use of BTX in conditions with muscle overactivity, such as dystonia and spasticity, has been established and new areas in the field of movement disorders such as tics, tremor, myoclonic jerks, and stuttering has been explored with satisfactory results. Strategies to temporarily inactivate muscle function after orthopaedic or neurosurgery have also been developed. BTX treatment of hyperhidrosis was followed by its application in other hypersecretory conditions (hyperlacrimation and nasal hypersecretion) and in excessive drooling. Studies are in progress, aimed at optimising the technique and protocol of administration. Other applications for BTX have been proposed in gastroenterological and urogenital practice; it appears to be effective in replacing standard surgical procedures. Trials of BTX in painful conditions are ongoing mainly on refractory tension headache, migraine, and backache as well as dystonia‐complex regional pain syndrome and myofascial pain with promising results. Recently, the fastest growing use for BTX toxin has been in the cosmetic applications. Clearly, the indications for the use of BTX are expanding, but further clinical trials will be needed in many different areas. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20071
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001E94
Links to Exploration step
ISTEX:1D037C61F1DE1CB7B4C0E5F3DDB0F8ACC6658B0FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">New therapeutic indications for botulinum toxins</title><author><name sortKey="Cordivari, Carla" sort="Cordivari, Carla" uniqKey="Cordivari C" first="Carla" last="Cordivari">Carla Cordivari</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, Windeyer Building, University College of London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, Windeyer Building, University College of London</wicri:regionArea></affiliation></author><author><name sortKey="Misra, V Peter" sort="Misra, V Peter" uniqKey="Misra V" first="V. Peter" last="Misra">V. Peter Misra</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Catania, Santiago" sort="Catania, Santiago" uniqKey="Catania S" first="Santiago" last="Catania">Santiago Catania</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, Windeyer Building, University College of London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, Windeyer Building, University College of London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1D037C61F1DE1CB7B4C0E5F3DDB0F8ACC6658B0F</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20071</idno><idno type="url">https://api.istex.fr/document/1D037C61F1DE1CB7B4C0E5F3DDB0F8ACC6658B0F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E94</idno><idno type="wicri:Area/Istex/Curation">001E94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">New therapeutic indications for botulinum toxins</title><author><name sortKey="Cordivari, Carla" sort="Cordivari, Carla" uniqKey="Cordivari C" first="Carla" last="Cordivari">Carla Cordivari</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, Windeyer Building, University College of London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, Windeyer Building, University College of London</wicri:regionArea></affiliation></author><author><name sortKey="Misra, V Peter" sort="Misra, V Peter" uniqKey="Misra V" first="V. Peter" last="Misra">V. Peter Misra</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Catania, Santiago" sort="Catania, Santiago" uniqKey="Catania S" first="Santiago" last="Catania">Santiago Catania</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, Windeyer Building, University College of London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, Windeyer Building, University College of London</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-03">2004-03</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">S8</biblScope><biblScope unit="page" from="S157">S157</biblScope><biblScope unit="page" to="S161">S161</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1D037C61F1DE1CB7B4C0E5F3DDB0F8ACC6658B0F</idno><idno type="DOI">10.1002/mds.20071</idno><idno type="ArticleID">MDS20071</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>botulinum toxin</term><term>dystonia</term><term>hyperhidrosis</term><term>hypersalivation</term><term>myoclonus</term><term>pain</term><term>parkinsonism</term><term>tic</term><term>tremor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficacy of botulinum toxin (BTX) without systemic effects has led to the rapid development of applications in neuromuscular disorders, hyperactivity of sudomotor cholinergic‐mediated glandular function, and pain syndromes. The successful use of BTX in conditions with muscle overactivity, such as dystonia and spasticity, has been established and new areas in the field of movement disorders such as tics, tremor, myoclonic jerks, and stuttering has been explored with satisfactory results. Strategies to temporarily inactivate muscle function after orthopaedic or neurosurgery have also been developed. BTX treatment of hyperhidrosis was followed by its application in other hypersecretory conditions (hyperlacrimation and nasal hypersecretion) and in excessive drooling. Studies are in progress, aimed at optimising the technique and protocol of administration. Other applications for BTX have been proposed in gastroenterological and urogenital practice; it appears to be effective in replacing standard surgical procedures. Trials of BTX in painful conditions are ongoing mainly on refractory tension headache, migraine, and backache as well as dystonia‐complex regional pain syndrome and myofascial pain with promising results. Recently, the fastest growing use for BTX toxin has been in the cosmetic applications. Clearly, the indications for the use of BTX are expanding, but further clinical trials will be needed in many different areas. © 2004 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001E94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:1D037C61F1DE1CB7B4C0E5F3DDB0F8ACC6658B0F
|texte= New therapeutic indications for botulinum toxins
}}
| This area was generated with Dilib version V0.6.23. |  |